AAA Clinical Trial
Official title:
JAGUAR Trial (Outside United States; OUS): ObJective Analysis to GaUge EVAR Outcomes Through Randomization
Verified date | February 2024 |
Source | Endologix |
Contact | Noel DeSisto |
Phone | 864-270-8524 |
ndesisto[@]endologix.com | |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Prospective, randomized, multi-center study designed to evaluate the outcomes of commercially available contemporary EVAR in a real-world population. Patients will be randomized into two device cohorts and compared across the primary endpoints. Patients will be followed procedurally to discharge, at 1, 6, 12 months and annually through to 5 years (total follow-up commitment).
Status | Not yet recruiting |
Enrollment | 450 |
Est. completion date | December 2030 |
Est. primary completion date | December 2030 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 21 Years and older |
Eligibility | Inclusion Criteria: - Adult age 21 and older - Subjects with minimum of 2 year life expectancy - Subjects have signed the informed consent document - Subjects with unruptured infrarenal AAA who are assessed by the Investigator to be eligible for endovascular Abdominal Aortic Aneurysm Repair with the trial devices. - Patient must be able and willing to comply with all required follow-up exams. Exclusion Criteria: - Currently participating in another trial where the primary endpoint has not been reached yet. - Known allergy to any of the device components - Pregnant (females of childbearing potential only) - Known connective tissue disorders - Known active infection - Subjects with pre-existing EVAR, i.e., in need of repair/intervention of a previously failed EVAR. - Patient has other medical, social, or psychological conditions that, in the opinion of the investigator, preclude them from receiving the pre-treatment, required treatment, and post-treatment procedures and evaluations. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Endologix |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Participants with Freedom from Aneurysm-Related Complications (ARC) | Composite endpoint consisting of aneurysm-related death, aneurysm rupture, conversion to open surgery, type I and III endoleaks, device migration (>10mm), aneurysm sac enlargement (>5mm), occlusion, and freedom from device-related interventions | Through 5 Years | |
Primary | Neck Dilation in mm | Through 5 Years | ||
Secondary | Number of Major Adverse Events (MAEs) | All-cause mortality, Bowel ischemia, Myocardial infarction, Paraplegia, Renal Failure, Respiratory Failure, Stroke, Index Procedural Blood Loss = 1000mL | [Time Frame: At 30 days and 12 months] | |
Secondary | Count of participants All Cause Mortality | At 30 days, 12 months, and annually up to five years | ||
Secondary | Count of participants AAA-related Mortality | At 30 days, 12 months, and annually up to five years | ||
Secondary | Number of Type Ia endoleaks | At 30 days, 12 months, and annually up to five years | ||
Secondary | Number of Type Ib | At 30 days, 12 months, and annually up to five years | ||
Secondary | Number of Type II | At 30 days, 12 months, and annually up to five years | ||
Secondary | Number of Type III | At 30 days, 12 months, and annually up to five years | ||
Secondary | Number of Type IV | At 30 days, 12 months, and annually up to five years | ||
Secondary | Number of Unknown Enooleaks | At 30 days, 12 months, and annually up to five years | ||
Secondary | Number of Secondary interventions | At 30 days, 12 months, and annually up to five years | ||
Secondary | Count of subjects lacking device integrity | device patency (stenosis and occlusion) and integrity (kinking, fracture, and polymer leak) | At 30 days, 12 months, and annually up to five years | |
Secondary | Count of aneurysm ruptures | At 30 days, 12 months, and annually up to five years | ||
Secondary | Count of participants with conversion to open surgery | At 30 days, 12 months, and annually up to five years | ||
Secondary | Count of participants with type I and III endoleaks | At 30 days, 12 months, and annually up to five years | ||
Secondary | Count of participants with device migration (>10mm) | 12 months, and annually up to five years | ||
Secondary | Count of participants with aneurysm sac enlargement (>5mm) | 12 months, and annually up to five years | ||
Secondary | Count of subjects with occlusion | 30 days, 12 months, and annually up to five years] | ||
Secondary | Number of Participants with Freedom From device-related interventions | 30 days, 12 months, and annually up to five years] |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05064540 -
JAGUAR Trial: ObJective Analysis to GaUge EVAR Outcomes Through Randomization
|
N/A | |
Completed |
NCT03762525 -
Iliac Branch Device Movement During Cardiac Cycle (IBD-dynamics)
|
N/A | |
Not yet recruiting |
NCT02843854 -
Safety and Efficacy of Allogeneic MSCs in Promoting T-regulatory Cells in Patients With Small Abdominal Aortic Aneurysms
|
Phase 1 | |
Completed |
NCT04080557 -
Abdominal Aortic Aneurysm Patients Remain at Risk for Delirium on the Surgical Ward After Intensive Care Unit Dismissal
|
||
Recruiting |
NCT02179801 -
Screening Cardiovascular Patients for Aortic aNeurysms (SCAN)
|
N/A | |
Recruiting |
NCT05376514 -
Central Blood Pressure and Variability Evaluation
|
||
Active, not recruiting |
NCT05133492 -
First In Human Study for Small to Medium-sized Abdominal Aortic Aneurysm (AAA)
|
N/A | |
Terminated |
NCT02485496 -
E-tegra Stent Graft System in the Treatment of Infra-renal Abdominal Aortic Aneurysms
|
||
Terminated |
NCT02461524 -
Endurant Evo International Clinical Trial
|
N/A | |
Not yet recruiting |
NCT03407664 -
NHS AAA Screening Programme Data Linkage With HES and ONS Datasets
|
||
Active, not recruiting |
NCT02692664 -
Prospective Multicenter Study for the Endovascular Treatment of Iliac Aneurysm With the Branched E-liac Stent Graft
|
||
Terminated |
NCT02393716 -
Endurant Evo US Clinical Trial
|
N/A |